Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

NCT00113529 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Gefitinib + Sunitinib

Sponsor

Pfizer